Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
BOSTON, May 01, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2018.
Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 6639039. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 7:30 p.m. ET on May 8, 2018 through May 15, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 6639039.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company’s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Media
Krystle Gibbs
Ten Bridge Communications
[email protected]
508-479-6358
Investors
John Woolford
Westwicke Partners
[email protected]
443-213-0506
